Development of dry powder inhaler containing tadalafil-loaded PLGA nanoparticles

Jaleh Varshosaz, Somayeh Taymouri, Hamed Hamishehkar, Razieh Vatankhah, Shadi Yaghubi


Inhalable dry powders containing poly lactic-co-glycolic acid (PLGA) nanoparticles (NPs) were developed for the delivery of tadalafil (TAD) for treatment of life-treating pulmonary arterial hypertension. Taguchi design was employed to evaluate the effects of different formulation variables on the physicochemical characteristics of PLGA-NPs prepared using emulsion solvent evaporation method. Inhalable PLGA-NPs of TAD were successfully prepared by co-spray drying the PLGA-NPs with inert carriers. Physicochemical characteristics and in vitro deposition of the aerosolized drug were also evaluated. The optimized formulation was prepared using 7.5 mg of PLGA, 2.5 mg of TAD, sonication time of 6 min and 2% polyvinyl alcohol (PVA) as the stabilizer. The optimized aqueous/oil phase ratio for PLGA-NPs preparation was 10:1. Polymer/drug ratio was the most effective parameter on the release efficiency. Encapsulation efficiency, zeta potential and particle size of PLGA-NPs were more affected by aqueous/organic phase ratio. The spray dried powders containing PLGA-NPs had a mass median aerodynamic diameter (MMAD) in the range of 1.4–2.8 µm that was suitable for TAD delivery to the deep region of lung. The presence of L-leucine in mannitol containing formulations decreased the interparticulate forces between particles and increased significantly the process yield and fine particle fraction (FPF). The results indicated that prepared dry powders containing TAD-loaded PLGA-NPs were suitable for inhalation and has the potential for the treatment of pulmonary arterial hypertension.


Tadalafil; PLGA; Nanoparticles; Spray drying; Dry powder inhaler

Full Text:



Ramakrishnan S. Current concepts in management of pulmonary hypertension: fighting the old demon with modern weapons. Indian J Pediatr. 2015;82(12):1128-1134.

Paranjpe M, Neuhaus V, Finke JH, Richter C, Gothsch T, Kwade A, et al. Toxicity testing of sildenafil base-loaded liposomes in in vitro and ex vivo models for pulmonary application. Inhal Toxicol. 2013;25(9):536-543

Ghasemian E, Vatanara A, Rouini MR, Rouholamini Najafabadi A, Gilani K, Lavasani H, et al. Inhaled sildenafil nanocomposites; lung accumulation and pulmonary pharmacokinetics. Pharm Dev Technol. 2016;21(8):961-971.

Baek JS, Pham CV, Myung CS, Cho CW. Tadalafil-loaded nanostructured lipid carriers using permeation enhancers. Int J Pharm. 2015;495(2):701-719.

Hassanpour Aghdam M, Ghanbarzadeh S, Javadzadeh Y, Hamishehkar H. Aggregated nanotransfersomal dry powder inhalation of itraconazole for pulmonary drug delivery. Adv Pharm Bull. 2016;6(1):57-64.

Iyer R, Hsia CC, Nguyen KT. Nano-therapeutics for the lung: state-of-the-art and future perspectives. Curr Pharm Des. 2015;21(36):5233-5244.

Li YZ, Sun X, Gong T, Liu J, Zuo J, Zhang ZR. Inhalable microparticles as carriers for pulmonary delivery of thymopentin-loaded solid lipid nanoparticles. Pharm Res. 2010;27(9):1977-1986.

Bohr A, Water J, Beck-Broichsitter M, Yang M. Nanoembedded microparticles for stabilization and delivery of drug-loaded nanoparticles. Curr Pharm Des. 2015;21(40):5829-5844.

Emami J, Pourmashhadi A, Sadeghi H, Varshosaz J, Hamishehkar H. Formulation and optimization of celecoxib-loaded PLGA nanoparticles by the Taguchi design and their in vitro cytotoxicity for lung cancer therapy. Pharm Dev Technol. 2014:1-10.

Hadipour Moghaddam P, Ramezani V, Esfandi E, Vatanara A, Nabi-Meibodi M, Darabi M, et al. Development of a nano-micro carrier system for sustained pulmonary delivery of clarithromycin. Power Technol. 2013;239:478-83.

Varshosaz J, Taymouri S, Hamishehkar H. Fabrication of polymeric nanoparticles of poly (ethylene‐co‐vinyl acetate) coated with chitosan for pulmonary delivery of carvedilol. J Appl Polym Sci. 2014;131(1).

Taymouri S, Varshosaz J, Hassanzadeh F, Haghjooy Javanmard S, Dana N. Optimisation of processing variables effective on self-assembly of folate targeted Synpronic-based micelles for docetaxel delivery in melanoma cells. IET Nanobiotechnol. 2015;9(5):306-313.

Mashak A, Mobedi H, Mahdavi H. A Comparative Study of Progesterone and Lidocaine Hydrochloride Release from Poly (L-lactide) Films. Pharm Sci. 2015;21(2):77-85.

Gómez-Gaete C, Tsapis N, Besnard M, Bochot A, Fattal E. Encapsulation of dexamethasone into biodegradable polymeric nanoparticles. Int J Pharm. 2007;331(2):153-159.

Emami HM, Hamishehkar H, Varshosaz J. Formulation and optimization of solid lipid nanoparticle formulation for pulmonary delivery of budesonide using Taguchi and Box-Behnken design. Res Pharm Sci. 2014;10(1):17-33.

Javadzadeh Y, Ahadi F, Davaran S, Mohammadi G, Sabzevari A, Adibkia K. Preparation and physicochemical characterization of naproxen-PLGA nanoparticles. Colloids Surf B. 2010;81(2):498-502.

Amaro MI, Tewes F, Gobbo O, Tajber L, Corrigan OI, Ehrhardt C, et al. Formulation, stability and pharmacokinetics of sugar-based salmon calcitonin-loaded nanoporous/nanoparticulate microparticles (NPMPs) for inhalation. Int J Pharm. 2015;483(1-2):6-18.

Iqbal M, Valour JP, Fessi H, Elaissari A. Preparation of biodegradable PCL particles via double emulsion evaporation method using ultrasound technique. Colloid Polym Sci. 2015;293(3):861-873.

Tripathi A, Gupta R, Saraf SA. PLGA nanoparticles of anti tubercular drug: drug loading and release studies of a water in-soluble drug. Int J Pharm Tech Res. 2010;2(3):2116-2123.

Gupta H, Aqil M, Khar RK, Ali A, Bhatnagar A, Mittal G. Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery. J Drug Target. 2011;19(6):409-417.

Duxfield L, Sultana R, Wang R, Englebretsen V, Deo S, Swift S, et al. Development of gatifloxacin-loaded cationic polymeric nanoparticles for ocular drug delivery. Pharm Dev Technol. 2016;21(2):172-179.

Sharma N, Madan P, Lin S. Effect of process and formulation variables on the preparation of parenteral paclitaxel-loaded biodegradable polymeric nanoparticles: A co-surfactant study. Asian J Pharm Sci. 2016;11(3):404-416.

Manoochehri S, Darvishi B, Kamalinia G, Amini M, Fallah M, Ostad SN, et al. Surface modification of PLGA nanoparticles via human serum albumin conjugation for controlled delivery of docetaxel. Daru. 2013 17;21(1):58.

Bosquillon C, Rouxhet PG, Ahimou F, Simon D, Culot C, Préat V, et al. Aerosolization properties, surface composition and physical state of spray-dried protein powders. J Control Release. 2004;99(3):357-367.

Wang L, Zhang Y, Tang X. Characterization of a new inhalable thymopentin formulation. Int J Pharm. 2009;375(1):1-7.

Sou T, Orlando L, McIntosh MP, Kaminskas LM, Morton DA. Investigating the interactions of amino acid components on a mannitol-based spray-dried powder formulation for pulmonary delivery: a design of experiment approach. Int J Pharm. 2011;421(2):220-229.

Lechuga-Ballesteros D, Charan C, Stults CL, Stevenson CL, Miller DP, Vehring R, et al. Trileucine improves aerosol performance and stability of spray-dried powders for inhalation. J Pharm Sci. 2008;97(1):287-302.


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.